About This Continuing Medical Education Activity

David Wyles; Mark S. Sulkowski; Douglas Dieterich

doi:10.1093/cid/ciw218

About This Continuing Medical Education Activity

David Wyles, Mark S. Sulkowski, Douglas Dieterich

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S1-S2
Journal	Clinical Infectious Diseases
Volume	63
DOIs	https://doi.org/10.1093/cid/ciw218
State	Published - 1 Jul 2016

Access to Document

10.1093/cid/ciw218

Cite this

@article{c1cf7d7180384629b4622c83b82cc04d,

title = "About This Continuing Medical Education Activity",

author = "David Wyles and Sulkowski, {Mark S.} and Douglas Dieterich",

note = "Funding Information: Supplement sponsorship. This article appears as part of the supplement “Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.” This activity is accredited by the University of Cincinnati. This activity is provided by the Chronic Liver Disease Foundation. This activity is supported by an educational grant from Merck & Co. Funding Information: David Wyles, MD, is Associate Professor of Medicine in the Division of Infectious Diseases at the University of California San Diego, La Jolla, California. Dr Wyles has served as an advisor to AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck. Dr Wyles{\textquoteright}s institution has received grant support from AbbVie, Bristol-Myers Squibb, Gilead, Merck, and Tacere. Funding Information: Jennifer Kiser, PharmD, is Associate Professor in the Department of Pharmaceutical Sciences at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado. Dr Kiser{\textquoteright}s institution has received grant support from Janssen. Dr Kiser{\textquoteright}s spouse has served on the speaker{\textquoteright}s bureau for Astellas.",

year = "2016",

month = jul,

day = "1",

doi = "10.1093/cid/ciw218",

language = "English",

volume = "63",

pages = "S1--S2",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - About This Continuing Medical Education Activity

AU - Wyles, David

AU - Sulkowski, Mark S.

AU - Dieterich, Douglas

N1 - Funding Information: Supplement sponsorship. This article appears as part of the supplement “Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.” This activity is accredited by the University of Cincinnati. This activity is provided by the Chronic Liver Disease Foundation. This activity is supported by an educational grant from Merck & Co. Funding Information: David Wyles, MD, is Associate Professor of Medicine in the Division of Infectious Diseases at the University of California San Diego, La Jolla, California. Dr Wyles has served as an advisor to AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck. Dr Wyles’s institution has received grant support from AbbVie, Bristol-Myers Squibb, Gilead, Merck, and Tacere. Funding Information: Jennifer Kiser, PharmD, is Associate Professor in the Department of Pharmaceutical Sciences at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado. Dr Kiser’s institution has received grant support from Janssen. Dr Kiser’s spouse has served on the speaker’s bureau for Astellas.

PY - 2016/7/1

Y1 - 2016/7/1

UR - http://www.scopus.com/inward/record.url?scp=85053045095&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw218

DO - 10.1093/cid/ciw218

M3 - Article

C2 - 27363436

AN - SCOPUS:85053045095

SN - 1058-4838

VL - 63

SP - S1-S2

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -